On December 2, 2024, the Reporting Persons and other unrelated investors entered into a Securities Purchase Agreement with the Issuer (the "Purchase Agreement"), pursuant to which the Reporting Persons purchased (i) 2,222 shares of the Issuer's Series A Preferred Stock (the "Series A") for an aggregate offering price of approximately $5.5 million and (ii) a warrant (the "Warrant") to purchase 3,333,000 shares of Issuer's Common Stock exercisable thereunder (the " Warrant Shares"). The Warrant has an exercise price per share of $2.30. The Warrant is exercisable at any time and from time to time on or after the Stockholder Approval (as defined below) until the five-year anniversary of the Warrant's issue date. BHC may not exercise the Warrant if BHC, together with its affiliates, would beneficially own more than 19.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise. BHC may increase or decrease this percentage not in excess of 45.00% by providing at least 61 days' prior notice to the Issuer. Subject to the terms and limitations contained in the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the "Certificate of Designation") governing the Series A, the Series A will not become convertible until the Issuer's stockholders approve (i) the issuance of all Common Stock issuable upon conversion of the Series A and (ii) the issuance of the Warrant Shares upon exercise of the Warrant (collectively, the "Stockholder Approval"). On the first trading day following the announcement of the Stockholder Approval, the Issuer may, at its option, cause each share of Series A to automatically convert into such number of shares of Common Stock, at the conversion price of $2.25 per share (the "Conversion Price"), subject to the terms and limitations contained in the Certificate of Designation. Additionally, subject to the terms and limitations in the Certificate of Designation, if the Issuer has not elected to automatically convert the Series A, then at the option of each individual holder of Series A, each share of the Series A held by such holder, not otherwise converted, shall be convertible into the applicable number of shares of Common Stock at the Conversion Price. On March 6, 2025, the Issuer's stockholders approved, among other things, subject to certain conditions, the issuance of the Issuer's outstanding Common Stock in accordance with Nasdaq Listing Rule 5635, upon (i) the conversion of the Series A pursuant to the terms of the Certificate of Designation and (ii) the exercise of Warrants and the underlying Warrant Shares at less than the "minimum price" under Nasdaq Listing Rule 5635(d), and each of (i) and (ii) which may be deemed a "change of control" under Nasdaq Listing Rule 5635(b), including the issuance of equity compensation to one of the Issuer's officers upon conversion of the Series A and the exercise of the Warrants to purchase Warrant Shares at less than market value under Nasdaq Listing Rule 5635(c). On March 10, 2025, following the Stockholder Approval, the Issuer exercised its option to automatically convert each share of Series A into 1,000 shares of Common Stock. Accordingly, BHC owns 2,809,848 shares of the Issuer's Common Stock. Further, BHC also has a right to exercise its Warrant to purchase 3,333,000 Warrant Shares but since the BHC's ownership as of the date of this filing is in excess of the 19.99% beneficial ownership limitation only a portion of the Warrant Shares, 2,980,148, are exercisable as of the date of this filing. The foregoing description is qualified in its entirety by the full text and form of the Certificate of Designation, the Warrant, and the Purchase Agreement, copies of which are filed herewith as Exhibits 7.03, 7.04 and 7.05, respectively. The source of the funds for the purchases by BHC described above was from available cash on hand.

The information set forth in Items 3 and 4 of this Schedule 13D is incorporated herein by reference. Registration Rights Agreement On December 2, 2024, in connection with the execution of the Purchase Agreement, the Issuer entered into a Registration Rights Agreement (the "Registration Rights Agreement") with certain investors (collectively the "Holders"), including the Reporting Persons, pursuant to which the Issuer has agreed, subject to the terms and conditions of the agreement, to file a registration statement under the Securities Act of 1933, as amended, promptly and, in any event, no later than 120 days after the Closing Date (as defined under the Purchase Agreement) to register the resale of the shares of Common Stock beneficially owned by the Holders, including all shares of Common Stock held by the Reporting Persons, as well as the shares issuable upon exercise of the Warrant held by the Reporting Persons. The Registration Rights Agreement also includes customary provisions, including with respect to the payment of fees and expenses associated with the registration, as well as indemnification provisions. The foregoing description is qualified in its entirety by the full text and form of the Registration Rights Agreement, a copy of which is filed herewith as Exhibit 7.06 and incorporated herein by reference.

Exhibit 7.01 - Joint Filing Agreement by and among the Reporting Persons. Exhibit 7.02 - Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended. Exhibit 7.03 - Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Issuer's Current Report on Form 8-K (File No.001-40440), filed on December 2, 2024). Exhibit 7.04 - Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.1 to the Issuer's Current Report on Form 8-K (File No.001-40440), filed on December 2, 2024). Exhibit 7.05 - Form of Securities Purchase Agreement, dated December 2, 2024, by and among Senti Biosciences, Inc. and the purchasers named therein (incorporated by reference to Exhibit 10.1 to the Issuer's Current Report on Form 8-K (File No.001-40440), filed on December 2, 2024). Exhibit 7.06 - Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to the Issuer's Current Report on Form 8-K (File No.001-40440), filed on December 2, 2024).